摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-Hydroxy-2-[(S)-7-(5-(4-(5-oxazolyl)phenyl)-2-thienyl)-1,1-dioxoperhydro-4-(1-pyrrolidinylsulfonyl)-1,4-thiazepin-7-yl]acetamide | 355845-23-7

中文名称
——
中文别名
——
英文名称
N-Hydroxy-2-[(S)-7-(5-(4-(5-oxazolyl)phenyl)-2-thienyl)-1,1-dioxoperhydro-4-(1-pyrrolidinylsulfonyl)-1,4-thiazepin-7-yl]acetamide
英文别名
N-hydroxy-2-[(7S)-7-[5-[4-(1,3-oxazol-5-yl)phenyl]thiophen-2-yl]-1,1-dioxo-4-pyrrolidin-1-ylsulfonyl-1,4-thiazepan-7-yl]acetamide
N-Hydroxy-2-[(S)-7-(5-(4-(5-oxazolyl)phenyl)-2-thienyl)-1,1-dioxoperhydro-4-(1-pyrrolidinylsulfonyl)-1,4-thiazepin-7-yl]acetamide化学式
CAS
355845-23-7
化学式
C24H28N4O7S3
mdl
——
分子量
580.707
InChiKey
KLDLZDYPKIYKPA-DEOSSOPVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    38
  • 可旋转键数:
    7
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    195
  • 氢给体数:
    2
  • 氢受体数:
    11

文献信息

  • Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors
    申请人:——
    公开号:US20030134849A1
    公开(公告)日:2003-07-17
    A compound of formula (I) in which R 1 is halo, lower alkoxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterecyclic group or optionally substituted lower alkynyl, R 2 is amidated carboxy, R 3 is hydrogen or acyl, Ar is aryl or heterocyclic group, X is thia, sulfinyl or sulfonyl, Y and Z are each lower alkylene, m and n are each an integer of 0 to 2, and a salt thereof, useful as inhibitors of matrix metalloproteinases (MMP) or the production of tumor necrosis factor &agr; (TNF &agr;).
    式(I)的化合物,其中R1是卤素、低碳氧基、可选取代芳基、可选取代芳氧基、可选取代杂环基或可选取代低炔基,R2是酰胺化羧基,R3是氢或酰基,Ar是芳基或杂环基,X是代、亚砜基或磺酰基,Y和Z是各自的低碳链基,m和n分别是0到2的整数,以及其盐,用作基质蛋白酶(MMP)抑制剂或肿瘤坏死因子α(TNFα)的产生。
  • US6967197B2
    申请人:——
    公开号:US6967197B2
    公开(公告)日:2005-11-22
  • [EN] NEW USE OF CYCLIC COMPOUND<br/>[FR] NOUVELLE UTILISATION DE COMPOSE CYCLIQUE
    申请人:FUJISAWA PHARMACEUTICAL CO
    公开号:WO2003018019A2
    公开(公告)日:2003-03-06
    An agent comprising a compound of Formula (I-a) and the like, or a salt thereof, use of a compound of Formula (I-a) and the like, or a salt thereof for the manufacture of a medicament, or a method comprising administering a compound of Formula (I-a) and the like, or a salt thereof, for the treatment of Inflammatory respiratory disease in which: Aa is a sulfonyl or a carbonyl; R1a is an optionally substituted aryl, etc; R2a is a hydrogen, etc; R3a is an optionally substituted lower alkyl, etc; R4a is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R5a is a hydrogen, etc; and R6a is a hydroxy or a protected hydroxy.
查看更多